慢性前列腺炎可预测慢性前列腺炎/慢性盆腔疼痛综合征患者的症状进展
在REDUCE安慰剂人群中,4年纵向分析显示急性与慢性前列腺炎症均与慢性前列腺炎/慢性盆腔疼痛综合征样症状的发生无关(p>0.1),但慢性炎症与基线已有该综合征患者症状进展时间缩短显著相关(单变量p=0.029,多变量p=0.018)。
要点
- 基线活检急性和慢性炎症分别见于641/4,109(15.6%)和3,216/4,109(78.3%)男性。
- 急性和慢性炎症与慢性前列腺炎/慢性盆腔疼痛综合征样症状发生无关(p>0.1)。
- 慢性而非急性炎症与基线已有该综合征患者症状进展时间缩短显著相关(p=0.029和0.018)。
核心结论
- 炎症与慢性前列腺炎/慢性盆腔疼痛综合征风险增加无关,但慢性炎症可预测已识别该综合征症状男性的症状进展风险。
研究设计与样本
- 对REDUCE(REduction by DUtasteride of prostate Cancer Events)人群中随机分配至安慰剂男性进行的4年纵向分析,在多个时间点行单变量和多变量分析。
主要发现
- 4,109名男性中急性炎症641名(15.6%),慢性炎症3,216名(78.3%)。
- 基线无该综合征且有随访数据的2,150名男性中317名出现慢性前列腺炎/慢性盆腔疼痛综合征样症状。
- 急性和慢性炎症与症状发生无关(p>0.1)。
- 中位随访12.0个月,基线有该综合征且有随访数据的145名男性中109名出现症状进展。
- 慢性而非急性炎症与进展时间缩短在单变量和多变量分析中显著相关(p=0.029和0.018)。
关键数值与推荐
- 慢性前列腺炎/慢性盆腔疼痛综合征样症状定义为CPSI(慢性前列腺炎症状指数)问题1a会阴痛和/或问题2b射精痛阳性且疼痛总分至少4分。
- 慢性前列腺炎/慢性盆腔疼痛综合征进展定义为基线已归类为该综合征患者CPSI总分较基线增加4分或以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We examined the 4-year longitudinal association between histological prostate inflammation and chronic prostatitis/chronic pelvic pain syndrome. We also studied the development of new and progressing existing chronic prostatitis/chronic pelvic pain syndrome in men randomized to placebo in the REDUCE (REduction by DUtasteride of prostate Cancer Events) population. MATERIALS AND METHODS: At multiple time points during 4 years univariable and multivariable analyses were performed between acute and chronic inflammation detected on baseline biopsies and the incidence of chronic pelvic pain syndrome-like symptoms, defined as a positive response to CPSI (Chronic Prostatitis Symptom Index) question 1a-perineal pain and/or question 2b-ejaculatory pain and a total pain subscore of at least 4, and progression of chronic prostatitis/chronic pelvic pain syndrome, defined as a 4-point or greater increase from baseline in total CPSI score, in patients with a baseline categorization of chronic prostatitis/chronic pelvic pain syndrome. RESULTS: Of the 4,109 men in the study acute and chronic inflammation was detected in 641 (15.6%) and 3,216 (78.3%), respectively. Chronic prostatitis/chronic pelvic pain syndrome symptom status was available for 2,816 at baseline. Chronic prostatitis/chronic pelvic pain syndrome-like symptoms developed in 317 of 2,150 men without the condition at baseline who had followup data. Acute and chronic inflammation was not associated with the incidence of the symptoms (p >0.1). At a median followup of 12.0 months 109 of 145 men with baseline chronic prostatitis/chronic pelvic pain syndrome and followup data showed symptomatic progression. Chronic but not acute inflammation was significantly associated with shorter time to progression on univariable and multivariable analyses (p = 0.029 and 0.018, respectively). CONCLUSIONS: Inflammation is not associated with an increased risk of chronic prostatitis/chronic pelvic pain syndrome. However, chronic inflammation predicts the risk of symptomatic progression in men in whom chronic prostatitis/chronic pelvic pain syndrome symptoms have been identified.
引用
- Nickel JC, Freedland SJ, Castro-Santamaria R, et al. Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic Pain. J Urol. 2017. PMID: 28089730. doi:10.1016/j.juro.2017.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。